Ralph Kern MD MHSc is currently Chief Medical Officer at Cognito Therapeutics. Previously he was President and Chief Medical Officer at BrainStorm Cell Therapeutics. Prior industry experience includes SVP and head of the global medical organization at Biogen; VP and head of the US Neuroscience Medical Unit at Novartis; and General Manager of the Fabrazyme biologics franchise at Genzyme.
Prior to joining the biotechnology industry, Ralph was head of the academic neurology program at the University of Toronto and led the clinical neurophysiology department at Mount Sinai Hospital in Toronto.
Ralph completed undergraduate education in neurophysiology at McGill University in Montreal Quebec, an MD from Queens’ University in Kingston Ontario, post-graduate neurology training at McGill University and the University College London UK, as well as a research fellowship in pediatric epilepsy and EEG at the Hospital for Sick Children in Toronto. Ralph completed the MHSc program in Health Administration from the Institute of Health Policy Management and Evaluation at the University of Toronto in 2003.